Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Lipocine Inc. (“Lipocine” or the “Company”) (Nasdaq: LPCN). Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 (the “Class Period”) are encouraged to contact the firm in advance of the August 30, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The complaint alleges that during the Class Period, the Company made false and/or misleading statements and/or failed to disclose that: Lipocine’s filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021 (the Company’s lead product candidate) contained deficiencies; and as a result, Lipocine’s statements about its business and operations were false and misleading and/or lacked a reasonable basis. When this information entered the market, investors suffered losses.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.